Vertical Cell Runs Up to Four Mini Gels in Less Than One Hour
HERCULES, CA — March 19, 2008 — Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics, today announced the new Bio-Rad Mini-PROTEAN® Tetra system for vertical mini gel electrophoresis. The cell can run up to 4 mini gels in less than hour or 2-D gels in less than a day.
Easy to assemble with a patented sealing mechanism to prevent leaks, the new Mini-PROTEAN Tetra cell system includes a convenient casting stand for hand casting and the ability to run either handcast or precast gels. The instrument"s interchangeable module design allows its tank to be used for protein transfer with a mini trans-blot module.
For added user convenience, the new Tetra cell lid is designed to ensure correct electrode polarity and electrode assembly orientation. Helpful guidelines are added on the tank to indicate how much buffer to add for two-gel and four-gel electrophoresis.
Availability
The new Mini-PROTEAN Tetra cell system can be ordered now with delivery taking from three days to one week. For more information on Bio-Rad's vertical electrophoresis cells, go to www.mytetracell.com
About Bio-Rad
Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues of nearly $1.3 billion in 2006. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as updated by subsequent place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements. Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.